宏源药业
(301246)
| 流通市值：36.79亿 | | | 总市值：61.80亿 |
| 流通股本：2.38亿 | | | 总股本：4.00亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,941,199,930.23 | 1,341,942,986.85 | 703,525,713.02 | 1,939,468,837.26 |
| 营业收入 | 1,941,199,930.23 | 1,341,942,986.85 | 703,525,713.02 | 1,939,468,837.26 |
| 二、营业总成本 | 1,737,107,761.79 | 1,156,301,588.45 | 543,865,867.35 | 1,794,917,960.56 |
| 营业成本 | 1,558,740,076.1 | 1,032,411,323.15 | 478,380,974.86 | 1,575,318,540.94 |
| 税金及附加 | 12,851,486.94 | 8,948,531.22 | 4,657,198.23 | 15,235,073.96 |
| 销售费用 | 34,039,515.38 | 24,866,974.53 | 11,851,769.06 | 47,628,250.54 |
| 管理费用 | 46,727,798.51 | 30,852,699.58 | 16,089,211.33 | 62,596,758.45 |
| 研发费用 | 73,736,447.11 | 51,742,269.19 | 29,342,302.03 | 83,900,358.56 |
| 财务费用 | 11,012,437.75 | 7,479,790.78 | 3,544,411.84 | 10,238,978.11 |
| 其中:利息费用 | 8,375,456.43 | 5,447,080.67 | 2,579,508.97 | 13,787,037.92 |
| 其中:利息收入 | 3,418,027.38 | 2,301,424.34 | 1,118,067.66 | 6,556,054.12 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -1,752,805.07 | -2,611,561.96 | 1,469,910.38 | 1,849,195.72 |
| 加:投资收益 | 51,648,661.36 | 38,073,357 | 23,263,185.41 | 31,064,704.62 |
| 资产处置收益 | -4,728,526.53 | -2,372,406.36 | -1,155,325.07 | 773,836.31 |
| 资产减值损失(新) | -10,594,855.44 | -6,797,035.58 | -3,805,823.46 | -40,087,507.9 |
| 信用减值损失(新) | -344,642.01 | -1,209,418.79 | -3,625,152.46 | -3,500,781.59 |
| 其他收益 | 15,179,462.79 | 11,101,953.45 | 7,820,746.16 | 23,616,949.8 |
| 四、营业利润 | 253,499,463.54 | 221,826,286.16 | 183,627,386.63 | 158,267,273.66 |
| 加:营业外收入 | 174,494.2 | 40,578.53 | 27,704.55 | 119,191.52 |
| 减:营业外支出 | 19,236,920.13 | 18,793,351.32 | 18,789,313.76 | 12,671,274.84 |
| 五、利润总额 | 234,437,037.61 | 203,073,513.37 | 164,865,777.42 | 145,715,190.34 |
| 减:所得税费用 | 51,293,813.9 | 47,583,208.05 | 20,668,210.84 | 28,085,468.21 |
| 六、净利润 | 183,143,223.71 | 155,490,305.32 | 144,197,566.58 | 117,629,722.13 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 183,143,223.71 | 155,490,305.32 | 144,197,566.58 | 117,629,722.13 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 184,236,864.87 | 156,238,212.74 | 144,347,585.08 | 119,053,394.74 |
| 少数股东损益 | -1,093,641.16 | -747,907.42 | -150,018.5 | -1,423,672.61 |
| 扣除非经常损益后的净利润 | 181,140,573.18 | 159,473,654.83 | 153,350,597.72 | 90,300,205.84 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.46 | 0.39 | 0.36 | 0.3 |
| (二)稀释每股收益 | 0.46 | 0.39 | 0.36 | 0.3 |
| 九、综合收益总额 | 183,143,223.71 | 155,490,305.32 | 144,197,566.58 | 117,629,722.13 |
| 归属于母公司股东的综合收益总额 | 184,236,864.87 | 156,238,212.74 | 144,347,585.08 | 119,053,394.74 |
| 归属于少数股东的综合收益总额 | -1,093,641.16 | -747,907.42 | -150,018.5 | -1,423,672.61 |
| 公告日期 | 2026-10-28 | 2026-08-28 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |